AnPac Bio-Medical: Rises on Chinese approval for COVID-19 test

Fresh2

02/11/2020 13:47

** U.S.-listed shares of Chinese biotech co  ANPC.O  surge
32% to $4.2 premarket; set for their best day in more than 2
months 
    ** Stock among top pct gainers across U.S. exchanges 
    ** China-based Jiangsu AnPac Health Management Co, in which
ANPC has a 15% stake, has received regulatory nod to conduct
COVID-19 nucleic acid tests  urn:newsml:reuters.com:*:nGNX247qxq
    ** Jiangsu AnPac has begun to receive samples for paid
COVID-19 nucleic acid tests- ANPC
    ** China is a top producer of nucleic acid tests
    ** Up to Friday's close, stock is flat YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))